320 related articles for article (PubMed ID: 29566065)
1. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
[TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
6. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
8. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
9. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
[TBL] [Abstract][Full Text] [Related]
11. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of filamin-A protein is associated with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.
Gachechiladze M; Skarda J; Janikova M; Mgebrishvili G; Kharaishvili G; Kolek V; Grygarkova I; Klein J; Poprachova A; Arabuli M; Kolar Z
Neoplasma; 2016; 63(2):274-81. PubMed ID: 26774150
[TBL] [Abstract][Full Text] [Related]
13. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer.
Van Laar RK
BMC Med Genomics; 2012 Jul; 5():30. PubMed ID: 22748043
[TBL] [Abstract][Full Text] [Related]
14. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
15. Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.
Sorensen SF; Carus A; Meldgaard P
Lung Cancer; 2015 May; 88(2):167-73. PubMed ID: 25769883
[TBL] [Abstract][Full Text] [Related]
16. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
[TBL] [Abstract][Full Text] [Related]
18. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
19. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.
Ceppi P; Novello S; Cambieri A; Longo M; Monica V; Lo Iacono M; Giaj-Levra M; Saviozzi S; Volante M; Papotti M; Scagliotti G
Clin Cancer Res; 2009 Feb; 15(3):1039-45. PubMed ID: 19188177
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T; Sakai K; Kenmotsu H; Yoh K; Daga H; Ohira T; Ueno T; Aoki T; Hayashi H; Yamazaki K; Hosomi Y; Chen-Yoshikawa TF; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Inokawa H; Yamamoto N; Nishio K; Tsuboi M
Cancer Sci; 2022 Jan; 113(1):287-296. PubMed ID: 34689382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]